Nutrien to sell stake in Argentina's Profertil for $600 million

Nutrien Ltd. announced the divestiture of its 50% equity stake in Argentina-based Profertil S.A. for approximately $600 million, a strategic move aimed at streamlining its portfolio and allocating proceeds towards growth investments, share repurchases, and debt reduction. This follows the company's Q2 2025 earnings, which saw an EPS beat of $2.65 against an expected $2.39, despite a slight revenue miss. Analyst sentiment remains mixed, with JPMorgan upgrading Nutrien to Overweight due to favorable fertilizer market conditions, while Jefferies adjusted its price target lower, reflecting diverse views on the company's future performance.

Analysis

Nutrien Ltd. is executing a strategic portfolio optimization by agreeing to sell its 50% equity stake in Profertil S.A. for approximately $600 million. This move is designed to streamline operations and focus on core assets, with management intending to deploy the proceeds towards growth investments, share repurchases, and debt reduction. The divested asset contributed approximately $60 million to Nutrien's Nitrogen segment earnings over the last four quarters, providing a benchmark for the valuation of the deal. This corporate action coincides with the company's Q2 2025 financial results, which presented a mixed but ultimately positive picture. Nutrien reported a significant earnings per share (EPS) of $2.65, surpassing analyst expectations of $2.39 by 10.88%, indicating strong operational efficiency or margin control. However, this was contrasted by a slight revenue shortfall, with revenues of $10.44 billion missing the $10.55 billion forecast. Analyst sentiment is notably divided, reflecting the complexity of the current situation. JPMorgan upgraded the stock to Overweight and raised its price target to $68.00, citing favorable fertilizer market dynamics such as low inventories and tight supply. Conversely, Jefferies maintained a Hold rating while reducing its price target from $66.00 to $61.00, suggesting a more cautious outlook despite the EPS beat.

Key Decisions for Investors

• Investors could interpret the strategic divestiture and strong EPS beat as positive catalysts, aligning with JPMorgan's Overweight rating, particularly for those with a bullish thesis on the underlying fertilizer market.
• The slight revenue miss and conflicting analyst outlook from Jefferies warrant attention; a key consideration is whether the earnings outperformance is sustainable without a corresponding recovery in top-line revenue growth.
• Closely monitor the deployment of the ~$600 million in proceeds from the Profertil sale, as management's execution on share repurchases, debt reduction, and accretive growth will be a key indicator of future shareholder value creation.